Clene Inc. (CLNN) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Clene Inc. is a clinical-stage pharmaceutical company developing clean-surfaced nanotechnology therapeutics, primarily for central nervous system disorders including ALS, Multiple Sclerosis (MS), and Parkinson's disease. The company generates minimal revenue from dietary supplements via its subsidiary dOrbital and a license agreement with 4Life Research LLC. On July 11, 2024, the company effected a 1-for-20 reverse stock split; all historical share data in this filing has been retroactively adjusted.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $0.091 million | $0.164 million | $0.269 million | $0.376 million |
| Net Loss | $(6.785) million | $(17.865) million | $(25.143) million | $(36.913) million |
| Loss Per Share (Basic/Diluted) | $(1.06) | $(2.78) | $(5.84) | $(9.11) |
| Operating Cash Flow | N/A | $(13.438) million | N/A | $(16.239) million |
| Cash & Equivalents (End of Period) | $21.682 million | $21.682 million | N/A | N/A |
| Total Debt (Notes Payable) | $22.198 million | $22.198 million | N/A | N/A |
| Accumulated Deficit | $(260.588) million | $(260.588) million | N/A | N/A |
Note: Revenue consists of product sales ($0.064M Q2) and royalties ($0.027M Q2). Operating expenses totaled $7.482 million for Q2 2024.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 66% in Q2 2024 compared to Q2 2023, driven by timing of purchases of dietary supplements by related party 4Life.
- Reduced Net Loss: Net loss improved significantly (73% reduction in Q2) primarily due to the absence of a $14.8 million "loss on initial issuance of equity" recorded in Q2 2023 related to a public offering.
- Operating Expenses: Total operating expenses decreased 29% year-over-year in Q2. Research and Development (R&D) expenses dropped 37% due to NIH grant reimbursements offsetting costs and the completion of blinded periods in several clinical trials.
- Debt Structure: The company holds a $20 million term loan from Avenue Venture Opportunities Fund, L.P., which matures December 1, 2024. The loan requires the company to maintain at least $5.0 million in unrestricted cash to avoid acceleration.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that its plans do not alleviate substantial doubt about the company's ability to continue as a going concern beyond one year. The company expects to incur additional losses and will require additional financing to sustain operations.
- Clinical Progress (ALS): New long-term data for CNM-Au8 showed a 60% decreased risk of death compared to matched controls. The company submitted a briefing book to the FDA for a Type C interaction in Q3 2024 to discuss an accelerated approval pathway.
- Clinical Progress (MS): Long-term extension data for VISIONARY-MS demonstrated sustained clinical benefits, including improvements in vision and cognition. A second dosing cohort for REPAIR-MS is ongoing.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting, specifically regarding the control environment, manual journal entries, and IT general controls. Remediation efforts are ongoing.
- Contingencies: The company holds contingent earn-out liabilities and potential repayment obligations for grants from the National Multiple Sclerosis Society (NMSS) if commercial sales milestones are met.
Investor Verification Checklist
- Liquidity Runway: Verify if the company has secured new financing to cover the $20 million Avenue loan maturing in December 2024 and ongoing operational burn.
- FDA Interaction Outcome: Monitor the results of the Q3 2024 FDA Type C meeting regarding the accelerated approval pathway for CNM-Au8 in ALS.
- Reverse Stock Split Impact: Confirm the trading volume and price stability of the stock following the 1-for-20 reverse stock split effective July 11, 2024.
- Internal Control Remediation: Review future filings for updates on the remediation of material weaknesses in financial reporting controls.
- Grant Reimbursements: Track the timing and amount of reimbursements from the NIH ACT-EAP grant, which significantly offset R&D expenses in the current period.